What is going on with BPC-157?
If you have been following regulatory news, you know things are moving fast. As of September 27, 2026, BPC-157 is officially under evolving review. It was previously placed in FDA Category 2, which means the FDA has identified potential significant safety concerns.
Specifically, the FDA is looking at immunogenicity (when your body has an immune response to a substance), peptide-related impurities, and a general lack of human safety data. In July 2026, the Pharmacy Compounding Advisory Committee reviewed BPC-157 to see if it should be added to the 503A Bulks List, which is a list of ingredients allowed for compounding.
The news on Semaglutide and GLP-1s
Semaglutide is FDA-approved under brand names like Ozempic and Wegovy. However, the national shortage-related compounding period has ended. This means pharmacists have to follow stricter rules about making copies of the drug.
FDA safety signals for semaglutide include:
- Nausea and Vomiting: Strong signals, but already listed on the label.
- Delayed Gastric Emptying: This can affect how your body absorbs other pills you take by mouth.
- Pancreatitis: A moderate signal that doctors monitor closely.
- Emerging Signals: New concerns like NAION (an eye condition) and Pulmonary Aspiration (breathing in foreign material) are being watched or added to labels.
In clinical trials, semaglutide showed a 14.9% weight loss in the STEP 1 study and a 20% reduction in major heart-related events in the SELECT trial.
Other peptides on the radar
Several other compounds were recently moved or reviewed. KPV was previously in Category 2, but that nomination was withdrawn. Like BPC-157, it was reviewed by the advisory committee in July 2026. The FDA still notes concerns regarding limited human exposure information.
Meanwhile, GHRP-2, GHRP-6, and MK-677 remain in Category 2 as of September 2023. These have faced immunogenicity concerns and received warning letters back in 2020. Even Melanotan II is under the spotlight due to multiple serious adverse events and safety warnings from the FDA and TGA.
How to act on this info
Scientists are still working on these—turns out the human body is complicated. Who knew? Because the rules around these compounds change frequently, this is a great one to bring up with your doctor.
If you are looking for guidance, you can learn how to find a peptide prescriber who understands these regulatory shifts. You can also find peptide-experienced physicians in our Find a Doctor directory.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.